What does this research mean for the field?

Idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, can result in irreversible parkinsonism as a rare neurotoxic adverse event. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 23, 2026Leukemia & lymphoma/Leukemia and lymphoma1 citations

View Full Paper

Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity

GPGrégorio PetrirenaAssistance Publique Hôpitaux de Marseille JSJean-Marc SchianoInstitut Paoli-Calmettes CLC LemarieInstitut Paoli-Calmettes

Key Points

Key points are not available for this paper at this time.

Abstract

B-cell maturation antigen (BCMA)-directed CAR T-cells are now an established option for relapsed or refractory multiple myeloma, with idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel ...

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity

Key Points

Abstract

Cite This Study

Also Consider

Also Consider